Management of Borderline Resectable Pancreatic Cancer

Management of Borderline Resectable Pancreatic Cancer With the rapid development of imaging modalities and surgical techniques, the clinical entity representing tumors that are intermediate between resectable and unresectable pancreatic adenocarcinoma has been identified has been termed “borderline resectable” (BR). These tumors are generally amenable for resection but portend an increased risk for positive margins after surgery and commonly necessitate vascular resection and reconstruction. Although there is a lack of consensus regarding the appropriate definition of what constitutes a BR pancreatic tumor, it has been demonstrated that this intermediate category carries a particular prognosis that is in between resectable and unresectable disease. In order to downstage the tumor and increase the probability of clear surgical margins, neoadjuvant therapy is being increasingly utilized and studied. There is a lack of high-level evidence to establish the optimal treatment regimen for BR tumors. When resection with negative margins is achieved after neoadjuvant therapy, the prognosis for BR tumors approaches and even exceeds that for resectable disease. This review presents the current definitions, different treatment approaches, and the clinical outcomes of BR pancreatic cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Radiation Oncology Biology Physics Elsevier

Management of Borderline Resectable Pancreatic Cancer

20 pages
Read Article

Loading next page...
 
/lp/elsevier/management-of-borderline-resectable-pancreatic-cancer-B8GCa4SHk3
Publisher
Elsevier
Copyright
Copyright © 2018 Elsevier Inc.
ISSN
0360-3016
D.O.I.
10.1016/j.ijrobp.2017.12.287
Publisher site
See Article on Publisher Site

Abstract

With the rapid development of imaging modalities and surgical techniques, the clinical entity representing tumors that are intermediate between resectable and unresectable pancreatic adenocarcinoma has been identified has been termed “borderline resectable” (BR). These tumors are generally amenable for resection but portend an increased risk for positive margins after surgery and commonly necessitate vascular resection and reconstruction. Although there is a lack of consensus regarding the appropriate definition of what constitutes a BR pancreatic tumor, it has been demonstrated that this intermediate category carries a particular prognosis that is in between resectable and unresectable disease. In order to downstage the tumor and increase the probability of clear surgical margins, neoadjuvant therapy is being increasingly utilized and studied. There is a lack of high-level evidence to establish the optimal treatment regimen for BR tumors. When resection with negative margins is achieved after neoadjuvant therapy, the prognosis for BR tumors approaches and even exceeds that for resectable disease. This review presents the current definitions, different treatment approaches, and the clinical outcomes of BR pancreatic cancer.

Journal

International Journal of Radiation Oncology Biology Physics – Elsevier

Published: Apr 1, 2018

References

  • Cancer statistics, 2017
    Siegel, R.L.; Miller, K.D.; Jemal, A.
  • Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States
    Rahib, L.; Smith, B.D.; Aizenberg, R.
  • Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients
    Kuhlmann, K.F.; de Castro, S.M.; Wesseling, J.G.
  • Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators
    Sohn, T.A.; Yeo, C.J.; Cameron, J.L.
  • Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial
    Neoptolemos, J.P.; Stocken, D.D.; Dunn, J.A.
  • 1423 Pancreaticoduodenectomies for pancreatic cancer: A single-institution experience
    Winter, J.M.; Cameron, J.L.; Campbell, K.A.
  • Advanced 3-D imaging for the evaluation of pancreatic cancer with multidetector CT
    Tamm, E.; Charnsangavej, C.; Szklaruk, J.
  • Diagnosis and staging of pancreatic tumors
    Faria, S.C.; Tamm, E.P.; Loyer, E.M.
  • The value of imaging techniques in the staging of pancreatic cancer
    Kulig, J.; Popiela, T.; Zajac, A.
  • Preoperative therapies for resectable and borderline resectable pancreatic cancer
    Varadhachary, G.R.
  • Borderline resectable pancreatic cancer: Definitions and management
    Lopez, N.E.; Prendergast, C.; Lowy, A.M.
  • Management of borderline resectable pancreatic cancer
    Katz, M.H.; Crane, C.H.; Varadhachary, G.
  • Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas
    Mehta, V.K.; Fisher, G.; Ford, J.A.
  • Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy
    Varadhachary, G.R.; Tamm, E.P.; Abbruzzese, J.L.
  • Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement
    Callery, M.P.; Chang, K.J.; Fishman, E.K.
  • Combined modality treatment of resectable and borderline resectable pancreas cancer: Expert consensus statement
    Abrams, R.A.; Lowy, A.M.; O'Reilly, E.M.
  • Pancreatic Adenocarcinoma (version 1.2017; February 24, 2017)
  • Current staging systems for pancreatic cancer
    Appel, B.L.; Tolat, P.; Evans, D.B.
  • Borderline resectable pancreatic cancer: Need for standardization and methods for optimal clinical trial design
    Katz, M.H.; Marsh, R.; Herman, J.M.
  • Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)
    Bockhorn, M.; Uzunoglu, F.G.; Adham, M.
  • Radiographic tumor–vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer
    Tran Cao, H.S.; Balachandran, A.; Wang, H.
  • A tumour score with multidetector spiral CT for venous infiltration in pancreatic cancer: Influence on borderline resectable
    Marinelli, T.; Filippone, A.; Tavano, F.
  • Pancreatic ductal adenocarcinoma radiology reporting template: Consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association
    Al-Hawary, M.M.; Francis, I.R.; Chari, S.T.
  • Non-metastatic pancreatic cancer: Resectable, borderline resectable, and locally advanced—Definitions of increasing importance for the optimal delivery of multimodality therapy
    Evans, D.B.; George, B.; Tsai, S.
  • Preoperative multidetector CT diagnosis of extrapancreatic perineural or duodenal invasion is associated with reduced postoperative survival after pancreaticoduodenectomy for pancreatic adenocarcinoma: Preliminary experience and implications for patient care
    Chang, S.T.; Jeffrey, R.B.; Patel, B.N.
  • Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: The evolving role of radiation
    Hoffe, S.; Rao, N.; Shridhar, R.
  • Leakage of the gastroenteric anastomosis after pancreatoduodenectomy
    Eshuis, W.J.; Tol, J.A.; Nio, C.Y.
  • Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial
    Neoptolemos, J.P.; Palmer, D.H.; Ghaneh, P.
  • Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Seufferlein, T.; Bachet, J.B.; Van Cutsem, E.
  • Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline
    Khorana, A.A.; Mangu, P.B.; Berlin, J.
  • Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: Analysis of perioperative outcome and survival
    Massucco, P.; Capussotti, L.; Magnino, A.
  • Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer
    Stokes, J.B.; Nolan, N.J.; Stelow, E.B.
  • Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer
    Takai, S.; Satoi, S.; Yanagimoto, H.
  • Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer
    Cho, I.R.; Chung, M.J.; Bang, S.
  • Neoadjuvant chemoradiation with gemcitabine for locally advanced pancreatic cancer
    Habermehl, D.; Kessel, K.; Welzel, T.
  • Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma
    Brown, K.M.; Siripurapu, V.; Davidson, M.
  • Defining venous involvement in borderline resectable pancreatic cancer
    Chun, Y.S.; Milestone, B.N.; Watson, J.C.
  • Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy
    Barugola, G.; Partelli, S.; Crippa, S.
  • Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer
    Kang, C.M.; Chung, Y.E.; Park, J.Y.
  • A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer
    Kim, E.J.; Ben-Josef, E.; Herman, J.M.
  • Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer
    Takahashi, H.; Ohigashi, H.; Gotoh, K.
  • Treatment strategy for borderline resectable pancreatic cancer with radiographic artery involvement
    Hirono, S.; Kawai, M.; Okada, K.I.
  • Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer
    McClaine, R.J.; Lowy, A.M.; Sussman, J.J.
  • NeoGemTax: Gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer
    Sahora, K.; Kuehrer, I.; Schindl, M.
  • NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer
    Sahora, K.; Kuehrer, I.; Eisenhut, A.
  • Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma
    Lee, J.L.; Kim, S.C.; Kim, J.H.
  • Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer
    Boone, B.A.; Steve, J.; Krasinskas, A.M.
  • Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: Results from a prospective multi-institutional phase 2 trial
    Motoi, F.; Ishida, K.; Fujishima, F.
  • Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: A retrospective cohort study
    Paniccia, A.; Edil, B.H.; Schulick, R.D.
  • Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival
    Rose, J.B.; Rocha, F.G.; Alseidi, A.
  • Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma
    Ielpo, B.; Duran, H.; Diaz, E.
  • Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
    Kim, S.S.; Nakakura, E.K.; Wang, Z.J.
  • Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact
    Murakami, Y.; Uemura, K.; Sudo, T.
  • Phase I study of nab-paclitaxel plus gemcitabine as neoadjuvant therapy for borderline resectable pancreatic cancer
    Okada, K.I.; Hirono, S.; Kawai, M.
  • FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
    Conroy, T.; Desseigne, F.; Ychou, M.
  • Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
    Von Hoff, D.D.; Ervin, T.; Arena, F.P.
  • Borderline resectable pancreatic cancer: The importance of this emerging stage of disease
    Katz, M.H.; Pisters, P.W.; Evans, D.B.
  • Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma
    Landry, J.; Catalano, P.J.; Staley, C.
  • Comparison of 1-, 2-, and 3-dimensional tumor response assessment after neoadjuvant GTX-RT in borderline-resectable pancreatic cancer
    Chuong, M.D.; Hayman, T.J.; Patel, M.R.
  • Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer
    Patel, M.; Hoffe, S.; Malafa, M.
  • 5-FU/leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic cancer
    Kharofa, J.; Kelly, T.R.; Ritch, P.S.
  • Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: A single institutional experience
    Leone, F.; Gatti, M.; Massucco, P.
  • Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor–vessel relationships
    Dholakia, A.S.; Hacker-Prietz, A.; Wild, A.T.
  • Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: A new treatment paradigm?
    Christians, K.K.; Tsai, S.; Mahmoud, A.
  • Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer
    Kharofa, J.; Tsai, S.; Kelly, T.
  • Induction chemotherapy followed by concurrent full-dose gemcitabine and intensity-modulated radiation therapy for borderline resectable and locally advanced pancreatic adenocarcinoma
    Badiyan, S.N.; Olsen, J.R.; Lee, A.Y.
  • Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology trial A021101
    Katz, M.H.; Shi, Q.; Ahmad, S.A.
  • Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial
    Hammel, P.; Huguet, F.; van Laethem, J.L.
  • Accelerated fraction radiotherapy with capecitabine as neoadjuvant therapy for borderline resectable pancreatic cancer
    Chakraborty, S.; Morris, M.M.; Bauer, T.W.
  • Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma
    Takeda, Y.; Nakamori, S.; Eguchi, H.
  • Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer
    Prasad, S.; Cambridge, L.; Huguet, F.
  • Dose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation
    Wang, L.S.; Shaikh, T.; Handorf, E.A.
  • Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: A phase I study
    Passoni, P.; Reni, M.; Cattaneo, G.M.
  • Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation
    Krishnan, S.; Chadha, A.S.; Suh, Y.
  • Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer
    Koong, A.C.; Le, Q.T.; Ho, A.
  • Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer
    Koong, A.C.; Christofferson, E.; Le, Q.T.
  • Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer
    Schellenberg, D.; Goodman, K.A.; Lee, F.
  • Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer
    Mahadevan, A.; Jain, S.; Goldstein, M.
  • Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer
    Schellenberg, D.; Kim, J.; Christman-Skieller, C.
  • Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma
    Herman, J.M.; Chang, D.T.; Goodman, K.A.
  • Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated
    Chuong, M.D.; Springett, G.M.; Freilich, J.M.
  • Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer
    Rajagopalan, M.S.; Heron, D.E.; Wegner, R.E.
  • Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma
    Mellon, E.A.; Hoffe, S.E.; Springett, G.M.
  • The role of stereotactic body radiation therapy for pancreatic cancer: A single-institution experience
    Moningi, S.; Dholakia, A.S.; Raman, S.P.
  • Outcomes of a clinical pathway for borderline resectable pancreatic cancer
    Rashid, O.M.; Pimiento, J.M.; Gamenthaler, A.W.
  • A phase 1 study of stereotactic body radiation therapy dose escalation for borderline resectable pancreatic cancer after modified FOLFIRINOX (NCT01446458)
    Shaib, W.L.; Hawk, N.; Cassidy, R.J.
  • Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer
    Chuong, M.D.; Frakes, J.M.; Figura, N.
  • A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma
    Hong, T.S.; Ryan, D.P.; Borger, D.R.
  • Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity
    Nichols, R.C.; George, T.J.; Zaiden, R.A.
  • Proton therapy and concomitant capecitabine for non-metastatic unresectable pancreatic adenocarcinoma
    Sachsman, S.; Nichols, R.C.; Morris, C.G.
  • Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer
    Shinoto, M.; Yamada, S.; Yasuda, S.
  • Carbon ion radiation therapy with concurrent gemcitabine for patients with locally advanced pancreatic cancer
    Shinoto, M.; Yamada, S.; Terashima, K.
  • Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
    Jones, S.; Zhang, X.; Parsons, D.W.
  • Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4(Dpc4) immunostaining with pattern of disease progression
    Crane, C.H.; Varadhachary, G.R.; Yordy, J.S.
  • Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer
    Esnaola, N.F.; Chaudhary, U.B.; O'Brien, P.
  • Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group
    Moore, M.J.; Goldstein, D.; Hamm, J.
  • CONKO-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: A multicenter randomized phase III trial
    Sinn, M.; Bahra, M.; Liersch, T.
  • Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma
    Van Buren, G.; Ramanathan, R.K.; Krasinskas, A.M.
  • A phase II trial of two durations of bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer
    Sahora, K.; Schindl, M.; Kuehrer, I.
  • Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: A single-centre, open-label, dose-finding, non-randomised, phase 1B trial
    Nywening, T.M.; Wang-Gillam, A.; Sanford, D.E.
  • Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies
    Chiaravalli, M.; Reni, M.; O'Reilly, E.M.
  • Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
    Granier, C.; De Guillebon, E.; Blanc, C.
  • PD-1 blockade in tumors with mismatch-repair deficiency
    Le, D.T.; Uram, J.N.; Wang, H.
  • Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
    Le, D.T.; Durham, J.N.; Smith, K.N.
  • Neoadjuvant interferon-based chemoradiation for borderline resectable and locally advanced pancreas cancer: A phase II pilot study
    Jensen, E.H.; Armstrong, L.; Lee, C.
  • Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma
    Royal, R.E.; Levy, C.; Turner, K.
  • Neoadjuvant chemoradiotherapy for locally advanced pancreas cancer rarely leads to radiological evidence of tumour regression
    Dudeja, V.; Greeno, E.W.; Walker, S.P.
  • Pancreatic cancer: The microenvironment needs attention too!
    Apte, M.V.; Xu, Z.; Pothula, S.
  • Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer
    Ferrone, C.R.; Marchegiani, G.; Hong, T.S.
  • Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
    Katz, M.H.; Fleming, J.B.; Bhosale, P.
  • Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy
    Mellon, E.A.; Jin, W.H.; Frakes, J.M.
  • 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy
    Schellenberg, D.; Quon, A.; Minn, A.Y.
  • FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer
    Akita, H.; Takahashi, H.; Ohigashi, H.
  • Regional resection of cancer of the pancreas: A new surgical approach
    Fortner, J.G.
  • Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer
    Amano, R.; Kimura, K.; Nakata, B.
  • Arterial resection at the time of pancreatectomy for cancer
    Christians, K.K.; Pilgrim, C.H.; Tsai, S.
  • Advances in the surgical management of resectable and borderline resectable pancreas cancer
    Helmink, B.A.; Snyder, R.A.; Idrees, K.
  • Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: A meta-analysis
    Zhou, Y.; Zhang, Z.; Liu, Y.
  • Arterial resection during pancreatectomy for pancreatic cancer: A systematic review and meta-analysis
    Mollberg, N.; Rahbari, N.N.; Koch, M.
  • Distal pancreatectomy with celiac axis resection for carcinoma of the body and tail of the pancreas
    Takahashi, Y.; Kaneoka, Y.; Maeda, A.
  • Tips and tricks of the surgical technique for borderline resectable pancreatic cancer: Mesenteric approach and modified distal pancreatectomy with en-bloc celiac axis resection
    Hirono, S.; Yamaue, H.
  • Resection of locally advanced pancreatic cancer without regression of arterial encasement after modern-era neoadjuvant therapy
    Kluger, M.D.; Rashid, M.F.; Rosario, V.L.
  • Pancreatectomy with reconstruction of the right and left hepatic arteries for locally advanced pancreatic cancer
    Amano, H.; Miura, F.; Toyota, N.
  • Superior mesenteric artery (SMA) resection during pancreatectomy for malignant disease of the pancreas: A systematic review
    Jegatheeswaran, S.; Baltatzis, M.; Jamdar, S.
  • Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): Study protocol for a multicentre randomized controlled trial
    Versteijne, E.; van Eijck, C.H.; Punt, C.J.
  • Tumors of the Pancreas
    Hruban, R.H.; Pitman, M.B.; Klimstra, D.
  • Redefining the R1 resection in pancreatic cancer
    Verbeke, C.S.; Leitch, D.; Menon, K.V.
  • Most pancreatic cancer resections are R1 resections
    Esposito, I.; Kleeff, J.; Bergmann, F.
  • Definition of microscopic tumor clearance (R0) in pancreatic cancer resections
    Schlitter, A.M.; Esposito, I.
  • Meta-analysis of radical resection rates and margin assessment in pancreatic cancer
    Chandrasegaram, M.D.; Goldstein, D.; Simes, J.
  • Classification of R1 resections for pancreatic cancer: The prognostic relevance of tumour involvement within 1 mm of a resection margin
    Campbell, F.; Smith, R.A.; Whelan, P.
  • Studies of intraoperative radiotherapy in carcinoma of the pancreas
    Sindelar, W.F.; Kinsella, T.J.
  • Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer
    Zerbi, A.; Fossati, V.; Parolini, D.
  • Intraoperative radiation therapy of pancreatic carcinoma: A report of RTOG-8505. Radiation Therapy Oncology Group
    Tepper, J.E.; Noyes, D.; Krall, J.M.
  • Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer
    Willett, C.G.; Del Castillo, C.F.; Shih, H.A.
  • Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010
    Cai, S.; Hong, T.S.; Goldberg, S.I.
  • Preoperative chemoradiation and IOERT for unresectable or borderline resectable pancreas cancer
    Ashman, J.B.; Moss, A.A.; Rule, W.G.
  • Intraoperative radiotherapy for resected pancreatic cancer: A multi-institutional retrospective analysis of 210 patients
    Ogawa, K.; Karasawa, K.; Ito, Y.
  • Improved survival and local control after intraoperative radiation therapy and postoperative radiotherapy: A multivariate analysis of 46 patients undergoing surgery for pancreatic head cancer
    Alfieri, S.; Morganti, A.G.; Di Georgio, A.
  • Intraoperative radiotherapy in the era of intensive neoadjuvant chemotherapy and chemoradiotherapy for pancreatic adenocarcinoma
    Keane, F.K.; Wo, J.Y.; Ferrone, C.R.
  • The role of intraoperative radiation therapy in patients with pancreatic cancer
    Palta, M.; Willett, C.; Czito, B.
  • Locally advanced pancreatic cancer
    Willett, C.G.; Czito, B.G.; Bendell, J.C.
  • Health-related quality of life in SCALOP, a randomized phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer
    Hurt, C.N.; Mukherjee, S.; Bridgewater, J.
  • Prognostic value of SMAD4 in pancreatic cancer: A meta-analysis
    Shugang, X.; Hongfa, Y.; Jianpeng, L.
  • DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer
    Iacobuzio-Donahue, C.A.; Fu, B.; Yachida, S.

You’re reading a free preview. Subscribe to read the entire article.

Try 2 weeks free now

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

or browse the journals available

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial

Interested in DeepDyve for your group?
Try 2 weeks free now